Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-11-21

Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of ramucirumab (LY3009806) in participants with advanced hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Hepatocellular | Phase 1 | Status: COMPLETED | Results posted: 2018-11-21